ID   SIR5_HUMAN              Reviewed;         310 AA.
AC   Q9NXA8; B4DFM4; B4DYJ5; F5H5Z9; Q5T294; Q5T295; Q9Y6E6;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   12-APR-2017, entry version 144.
DE   RecName: Full=NAD-dependent protein deacylase sirtuin-5, mitochondrial {ECO:0000255|HAMAP-Rule:MF_03160};
DE            EC=3.5.1.- {ECO:0000255|HAMAP-Rule:MF_03160, ECO:0000269|PubMed:24703693};
DE   AltName: Full=Regulatory protein SIR2 homolog 5 {ECO:0000255|HAMAP-Rule:MF_03160};
DE   AltName: Full=SIR2-like protein 5 {ECO:0000255|HAMAP-Rule:MF_03160};
DE   Flags: Precursor;
GN   Name=SIRT5 {ECO:0000255|HAMAP-Rule:MF_03160}; Synonyms=SIR2L5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=10381378; DOI=10.1006/bbrc.1999.0897;
RA   Frye R.A.;
RT   "Characterization of five human cDNAs with homology to the yeast SIR2
RT   gene: Sir2-like proteins (sirtuins) metabolize NAD and may have
RT   protein ADP-ribosyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 260:273-279(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4).
RC   TISSUE=Amygdala, Hepatoblastoma, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16079181; DOI=10.1091/mbc.E05-01-0033;
RA   Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I.;
RT   "Evolutionarily conserved and nonconserved cellular localizations and
RT   functions of human SIRT proteins.";
RL   Mol. Biol. Cell 16:4623-4635(2005).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18680753; DOI=10.1016/j.jmb.2008.07.048;
RA   Schlicker C., Gertz M., Papatheodorou P., Kachholz B., Becker C.F.W.,
RA   Steegborn C.;
RT   "Substrates and regulation mechanisms for the human mitochondrial
RT   sirtuins Sirt3 and Sirt5.";
RL   J. Mol. Biol. 382:790-801(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   ALTERNATIVE SPLICING (ISOFORMS 1 AND 2), AND SUBCELLULAR LOCATION
RP   (ISOFORMS 1 AND 2).
RX   PubMed=21143562; DOI=10.1111/j.1365-2443.2010.01475.x;
RA   Matsushita N., Yonashiro R., Ogata Y., Sugiura A., Nagashima S.,
RA   Fukuda T., Inatome R., Yanagi S.;
RT   "Distinct regulation of mitochondrial localization and stability of
RT   two human Sirt5 isoforms.";
RL   Genes Cells 16:190-202(2011).
RN   [11]
RP   FUNCTION, NAD-BINDING, AND MUTAGENESIS OF HIS-158.
RX   PubMed=21908771; DOI=10.1074/mcp.M111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
RA   He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
RA   Dai J., Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [12]
RP   ENZYME REGULATION, AND MUTAGENESIS OF THR-69 AND ARG-105.
RX   PubMed=23028781; DOI=10.1371/journal.pone.0045098;
RA   Fischer F., Gertz M., Suenkel B., Lakshminarasimhan M.,
RA   Schutkowski M., Steegborn C.;
RT   "Sirt5 deacylation activities show differential sensitivities to
RT   nicotinamide inhibition.";
RL   PLoS ONE 7:E45098-E45098(2012).
RN   [13]
RP   FUNCTION.
RX   PubMed=24140062; DOI=10.1016/j.bbrc.2013.10.033;
RA   Lin Z.F., Xu H.B., Wang J.Y., Lin Q., Ruan Z., Liu F.B., Jin W.,
RA   Huang H.H., Chen X.;
RT   "SIRT5 desuccinylates and activates SOD1 to eliminate ROS.";
RL   Biochem. Biophys. Res. Commun. 441:191-195(2013).
RN   [14]
RP   SUBCELLULAR LOCATION.
RX   PubMed=23806337; DOI=10.1016/j.molcel.2013.06.001;
RA   Park J., Chen Y., Tishkoff D.X., Peng C., Tan M., Dai L., Xie Z.,
RA   Zhang Y., Zwaans B.M., Skinner M.E., Lombard D.B., Zhao Y.;
RT   "SIRT5-mediated lysine desuccinylation impacts diverse metabolic
RT   pathways.";
RL   Mol. Cell 50:919-930(2013).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-158.
RX   PubMed=24703693; DOI=10.1016/j.cmet.2014.03.014;
RA   Tan M., Peng C., Anderson K.A., Chhoy P., Xie Z., Dai L., Park J.,
RA   Chen Y., Huang H., Zhang Y., Ro J., Wagner G.R., Green M.F.,
RA   Madsen A.S., Schmiesing J., Peterson B.S., Xu G., Ilkayeva O.R.,
RA   Muehlbauer M.J., Braulke T., Muehlhausen C., Backos D.S., Olsen C.A.,
RA   McGuire P.J., Pletcher S.D., Lombard D.B., Hirschey M.D., Zhao Y.;
RT   "Lysine glutarylation is a protein posttranslational modification
RT   regulated by SIRT5.";
RL   Cell Metab. 19:605-617(2014).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 34-302 IN COMPLEX WITH NAD
RP   AND ZINC IONS.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human sirtuin homolog 5 in complex with NAD.";
RL   Submitted (FEB-2006) to the PDB data bank.
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.06 ANGSTROMS) OF 34-302 IN COMPLEXES WITH
RP   ZINC IONS; SURAMIN AND ADP-RIBOSE, CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, AND SUBUNIT.
RX   PubMed=17355872; DOI=10.1016/j.str.2007.02.002;
RA   Schuetz A., Min J., Antoshenko T., Wang C.-L., Allali-Hassani A.,
RA   Dong A., Loppnau P., Vedadi M., Bochkarev A., Sternglanz R.,
RA   Plotnikov A.N.;
RT   "Structural basis of inhibition of the human NAD+-dependent
RT   deacetylase SIRT5 by suramin.";
RL   Structure 15:377-389(2007).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 34-302 IN COMPLEX WITH NAD;
RP   ZINC IONS AND SUCCINYLATED PEPTIDE, COFACTOR, ACTIVE SITE,
RP   BIOPHYSICOCHEMICAL PROPERTIES, FUNCTION, CATALYTIC ACTIVITY, AND
RP   MUTAGENESIS OF TYR-102; ARG-105 AND HIS-158.
RX   PubMed=22076378; DOI=10.1126/science.1207861;
RA   Du J., Zhou Y., Su X., Yu J.J., Khan S., Jiang H., Kim J., Woo J.,
RA   Kim J.H., Choi B.H., He B., Chen W., Zhang S., Cerione R.A.,
RA   Auwerx J., Hao Q., Lin H.;
RT   "Sirt5 is a NAD-dependent protein lysine demalonylase and
RT   desuccinylase.";
RL   Science 334:806-809(2011).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 34-302 IN COMPLEX WITH NAD;
RP   ZINC IONS AND SUCCINYLATED PEPTIDE, AND REACTION MECHANISM.
RX   PubMed=22767592; DOI=10.1074/jbc.M112.384511;
RA   Zhou Y., Zhang H., He B., Du J., Lin H., Cerione R.A., Hao Q.;
RT   "The bicyclic intermediate structure provides insights into the
RT   desuccinylation mechanism of human sirtuin 5 (SIRT5).";
RL   J. Biol. Chem. 287:28307-28314(2012).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 36-302 IN COMPLEX WITH
RP   CARBA-NAD AND ZINC IONS.
RX   PubMed=22849721; DOI=10.1021/jo301067e;
RA   Szczepankiewicz B.G., Dai H., Koppetsch K.J., Qian D., Jiang F.,
RA   Mao C., Perni R.B.;
RT   "Synthesis of carba-NAD and the structures of its ternary complexes
RT   with SIRT3 and SIRT5.";
RL   J. Org. Chem. 77:7319-7329(2012).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 34-302 IN COMPLEX WITH
RP   PROTEIN PEPTIDE; ZINC IONS AND RESVERATROL, AND ENZYME REGULATION.
RX   PubMed=23185430; DOI=10.1371/journal.pone.0049761;
RA   Gertz M., Nguyen G.T., Fischer F., Suenkel B., Schlicker C.,
RA   Franzel B., Tomaschewski J., Aladini F., Becker C., Wolters D.,
RA   Steegborn C.;
RT   "A molecular mechanism for direct sirtuin activation by resveratrol.";
RL   PLoS ONE 7:E49761-E49761(2012).
CC   -!- FUNCTION: NAD-dependent lysine demalonylase, desuccinylase and
CC       deglutarylase that specifically removes malonyl, succinyl and
CC       glutaryl groups on target proteins (PubMed:21908771,
CC       PubMed:22076378, PubMed:24703693). Activates CPS1 and contributes
CC       to the regulation of blood ammonia levels during prolonged
CC       fasting: acts by mediating desuccinylation and deglutarylation of
CC       CPS1, thereby increasing CPS1 activity in response to elevated NAD
CC       levels during fasting (PubMed:22076378, PubMed:24703693).
CC       Activates SOD1 by mediating its desuccinylation, leading to
CC       reduced reactive oxygen species (PubMed:24140062). Modulates
CC       ketogenesis through the desuccinylation and activation of HMGCS2
CC       (By similarity). Has weak NAD-dependent protein deacetylase
CC       activity; however this activity may not be physiologically
CC       relevant in vivo. Can deacetylate cytochrome c (CYCS) and a number
CC       of other proteins in vitro such as UOX.
CC       {ECO:0000250|UniProtKB:Q8K2C6, ECO:0000269|PubMed:18680753,
CC       ECO:0000269|PubMed:21908771, ECO:0000269|PubMed:22076378,
CC       ECO:0000269|PubMed:24140062, ECO:0000269|PubMed:24703693}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + a malonylprotein = nicotinamide + O-
CC       malonyl-ADP-ribose + a protein. {ECO:0000255|HAMAP-Rule:MF_03160}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + a succinylprotein = nicotinamide + O-
CC       succinyl-ADP-ribose + a protein. {ECO:0000255|HAMAP-
CC       Rule:MF_03160}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + a glutarylprotein = nicotinamide + O-
CC       glutaryl-ADP-ribose + a protein. {ECO:0000255|HAMAP-Rule:MF_03160,
CC       ECO:0000269|PubMed:24703693}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_03160,
CC         ECO:0000269|PubMed:22076378};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000255|HAMAP-
CC       Rule:MF_03160, ECO:0000269|PubMed:22076378};
CC   -!- ENZYME REGULATION: Inhibited by suramin. NAD-dependent lysine
CC       desuccinylase activity is inhibited by physiological nicotinamide
CC       concentrations, while deacetylase activity is not. In contrast,
CC       resveratrol activates deacetylase activity, while inhibiting
CC       desuccinylase activity. {ECO:0000269|PubMed:17355872,
CC       ECO:0000269|PubMed:23028781, ECO:0000269|PubMed:23185430}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=6.1 uM for a synthetic histone H3K9 malonyllysine peptide
CC         {ECO:0000269|PubMed:22076378};
CC         KM=5.8 uM for a synthetic histone H3K9 succinyllysine peptide
CC         {ECO:0000269|PubMed:22076378};
CC         KM=8.7 uM for a synthetic GLUD1 peptide malonylated at 'Lys-503'
CC         {ECO:0000269|PubMed:22076378};
CC         KM=14 uM for a synthetic GLUD1 peptide succinylated at 'Lys-503'
CC         {ECO:0000269|PubMed:22076378};
CC         KM=150 uM for a synthetic ACSS1 peptide malonylated at 'Lys-628'
CC         {ECO:0000269|PubMed:22076378};
CC         KM=450 uM for a synthetic ACSS1 peptide succinylated at 'Lys-
CC         628' {ECO:0000269|PubMed:22076378};
CC   -!- SUBUNIT: Interacts with CPS1 (By similarity). Monomer. Homodimer.
CC       Forms homodimers upon suramin binding. {ECO:0000250,
CC       ECO:0000269|PubMed:17355872, ECO:0000269|PubMed:22076378,
CC       ECO:0000269|PubMed:22767592, ECO:0000269|PubMed:22849721,
CC       ECO:0000269|PubMed:23185430, ECO:0000269|Ref.17}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix. Mitochondrion
CC       intermembrane space. Cytoplasm, cytosol. Nucleus. Note=Mainly
CC       mitochondrial. Also present extramitochondrially, with a fraction
CC       present in the cytosol and very small amounts also detected in the
CC       nucleus.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm
CC       {ECO:0000269|PubMed:21143562}. Mitochondrion {ECO:0000255|HAMAP-
CC       Rule:MF_03160, ECO:0000269|PubMed:21143562}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Mitochondrion {ECO:0000255|HAMAP-
CC       Rule:MF_03160, ECO:0000269|PubMed:21143562}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9NXA8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NXA8-2; Sequence=VSP_008730, VSP_008731;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q9NXA8-3; Sequence=VSP_042292;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q9NXA8-4; Sequence=VSP_042291;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC       {ECO:0000269|PubMed:10381378}.
CC   -!- DOMAIN: In contrast to class I sirtuins, class III sirtuins have
CC       only weak deacetylase activity. Difference in substrate
CC       specificity is probably due to a larger hydrophobic pocket with 2
CC       residues (Tyr-102 and Arg-105) that bind to malonylated and
CC       succinylated substrates and define the specificity
CC       (PubMed:22076378). {ECO:0000269|PubMed:22076378}.
CC   -!- MISCELLANEOUS: The mechanism of demalonylation and desuccinylation
CC       involves the presence of a 1',2'-cyclic intermediate, suggesting
CC       that sirtuins use the ADP-ribose-peptidylamidate mechanism to
CC       remove acyl groups from substrate lysine residues.
CC       {ECO:0000305|PubMed:22767592}.
CC   -!- SIMILARITY: Belongs to the sirtuin family. Class III subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_03160}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF083110; AAD40853.1; -; mRNA.
DR   EMBL; AK000355; BAA91107.1; -; mRNA.
DR   EMBL; AK294162; BAG57485.1; -; mRNA.
DR   EMBL; AK302467; BAG63757.1; -; mRNA.
DR   EMBL; AM393414; CAL38292.1; -; mRNA.
DR   EMBL; AL441883; CAI19837.1; -; Genomic_DNA.
DR   EMBL; AL441883; CAI19838.1; -; Genomic_DNA.
DR   EMBL; CH471087; EAW55332.1; -; Genomic_DNA.
DR   EMBL; BC000126; AAH00126.1; -; mRNA.
DR   CCDS; CCDS4526.1; -. [Q9NXA8-1]
DR   CCDS; CCDS4527.1; -. [Q9NXA8-2]
DR   CCDS; CCDS54966.1; -. [Q9NXA8-3]
DR   CCDS; CCDS56398.1; -. [Q9NXA8-4]
DR   RefSeq; NP_001180196.1; NM_001193267.2. [Q9NXA8-3]
DR   RefSeq; NP_001229756.1; NM_001242827.1. [Q9NXA8-4]
DR   RefSeq; NP_036373.1; NM_012241.4. [Q9NXA8-1]
DR   RefSeq; NP_112534.1; NM_031244.3. [Q9NXA8-2]
DR   RefSeq; XP_005249025.1; XM_005248968.4. [Q9NXA8-1]
DR   UniGene; Hs.567431; -.
DR   UniGene; Hs.594133; -.
DR   PDB; 2B4Y; X-ray; 1.90 A; A/B/C/D=34-302.
DR   PDB; 2NYR; X-ray; 2.06 A; A/B=34-302.
DR   PDB; 3RIG; X-ray; 2.00 A; A/B=34-302.
DR   PDB; 3RIY; X-ray; 1.55 A; A/B=34-302.
DR   PDB; 4F4U; X-ray; 2.00 A; A/B=34-302.
DR   PDB; 4F56; X-ray; 1.70 A; A/B=34-302.
DR   PDB; 4G1C; X-ray; 1.94 A; A/B=36-302.
DR   PDB; 4HDA; X-ray; 2.60 A; A/B=34-302.
DR   PDB; 5BWL; X-ray; 1.55 A; A=33-302.
DR   PDBsum; 2B4Y; -.
DR   PDBsum; 2NYR; -.
DR   PDBsum; 3RIG; -.
DR   PDBsum; 3RIY; -.
DR   PDBsum; 4F4U; -.
DR   PDBsum; 4F56; -.
DR   PDBsum; 4G1C; -.
DR   PDBsum; 4HDA; -.
DR   PDBsum; 5BWL; -.
DR   ProteinModelPortal; Q9NXA8; -.
DR   SMR; Q9NXA8; -.
DR   BioGrid; 116980; 20.
DR   IntAct; Q9NXA8; 5.
DR   STRING; 9606.ENSP00000368552; -.
DR   BindingDB; Q9NXA8; -.
DR   ChEMBL; CHEMBL2163183; -.
DR   DrugBank; DB03478; 2'-O-Acetyl Adenosine-5-Diphosphoribose.
DR   DrugBank; DB02059; Adenosine-5-Diphosphoribose.
DR   DrugBank; DB02701; Nicotinamide.
DR   DrugBank; DB04786; Suramin.
DR   GuidetoPHARMACOLOGY; 2711; -.
DR   iPTMnet; Q9NXA8; -.
DR   PhosphoSitePlus; Q9NXA8; -.
DR   BioMuta; SIRT5; -.
DR   DMDM; 38258652; -.
DR   EPD; Q9NXA8; -.
DR   MaxQB; Q9NXA8; -.
DR   PaxDb; Q9NXA8; -.
DR   PeptideAtlas; Q9NXA8; -.
DR   PRIDE; Q9NXA8; -.
DR   DNASU; 23408; -.
DR   Ensembl; ENST00000359782; ENSP00000352830; ENSG00000124523. [Q9NXA8-3]
DR   Ensembl; ENST00000379262; ENSP00000368564; ENSG00000124523. [Q9NXA8-2]
DR   Ensembl; ENST00000397350; ENSP00000380509; ENSG00000124523. [Q9NXA8-4]
DR   Ensembl; ENST00000606117; ENSP00000476228; ENSG00000124523. [Q9NXA8-1]
DR   GeneID; 23408; -.
DR   KEGG; hsa:23408; -.
DR   UCSC; uc003naw.4; human. [Q9NXA8-1]
DR   CTD; 23408; -.
DR   DisGeNET; 23408; -.
DR   GeneCards; SIRT5; -.
DR   HGNC; HGNC:14933; SIRT5.
DR   HPA; HPA021798; -.
DR   HPA; HPA022002; -.
DR   HPA; HPA022992; -.
DR   MIM; 604483; gene.
DR   neXtProt; NX_Q9NXA8; -.
DR   OpenTargets; ENSG00000124523; -.
DR   PharmGKB; PA37938; -.
DR   eggNOG; KOG2684; Eukaryota.
DR   eggNOG; COG0846; LUCA.
DR   GeneTree; ENSGT00870000136443; -.
DR   HOGENOM; HOG000085950; -.
DR   HOVERGEN; HBG056009; -.
DR   InParanoid; Q9NXA8; -.
DR   KO; K11415; -.
DR   OMA; LIHMHGE; -.
DR   OrthoDB; EOG091G0KF2; -.
DR   PhylomeDB; Q9NXA8; -.
DR   TreeFam; TF106183; -.
DR   EvolutionaryTrace; Q9NXA8; -.
DR   GeneWiki; SIRT5; -.
DR   GenomeRNAi; 23408; -.
DR   PRO; PR:Q9NXA8; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000124523; -.
DR   CleanEx; HS_SIRT5; -.
DR   ExpressionAtlas; Q9NXA8; baseline and differential.
DR   Genevisible; Q9NXA8; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; IDA:UniProtKB.
DR   GO; GO:0005759; C:mitochondrial matrix; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; TAS:ProtInc.
DR   GO; GO:0070403; F:NAD+ binding; IDA:UniProtKB.
DR   GO; GO:0061697; F:protein-glutaryllysine deglutarylase activity; IDA:UniProtKB.
DR   GO; GO:0036054; F:protein-malonyllysine demalonylase activity; IDA:UniProtKB.
DR   GO; GO:0036055; F:protein-succinyllysine desuccinylase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006342; P:chromatin silencing; TAS:ProtInc.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0036047; P:peptidyl-lysine demalonylation; IDA:UniProtKB.
DR   GO; GO:0036049; P:peptidyl-lysine desuccinylation; IDA:UniProtKB.
DR   GO; GO:0006471; P:protein ADP-ribosylation; TAS:ProtInc.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0061698; P:protein deglutarylation; IDA:UniProtKB.
DR   GO; GO:0036046; P:protein demalonylation; IDA:UniProtKB.
DR   GO; GO:0036048; P:protein desuccinylation; IDA:UniProtKB.
DR   GO; GO:0010566; P:regulation of ketone biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   CDD; cd01412; SIRT5_Af1_CobB; 1.
DR   Gene3D; 3.40.50.1220; -; 1.
DR   HAMAP; MF_01121; Sirtuin_ClassIII; 1.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   InterPro; IPR003000; Sirtuin.
DR   InterPro; IPR027546; Sirtuin_class_III.
DR   InterPro; IPR026590; Ssirtuin_cat_dom.
DR   Pfam; PF02146; SIR2; 1.
DR   SUPFAM; SSF52467; SSF52467; 1.
DR   PROSITE; PS50305; SIRTUIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Hydrolase; Metal-binding; Mitochondrion; NAD; Nucleus; Polymorphism;
KW   Reference proteome; Transit peptide; Zinc.
FT   TRANSIT       1     36       Mitochondrion. {ECO:0000255|HAMAP-
FT                                Rule:MF_03160}.
FT   CHAIN        37    310       NAD-dependent protein deacylase sirtuin-
FT                                5, mitochondrial.
FT                                /FTId=PRO_0000110266.
FT   DOMAIN       41    309       Deacetylase sirtuin-type.
FT                                {ECO:0000255|HAMAP-Rule:MF_03160}.
FT   NP_BIND      58     77       NAD. {ECO:0000255|HAMAP-Rule:MF_03160,
FT                                ECO:0000269|PubMed:22076378,
FT                                ECO:0000269|PubMed:22767592,
FT                                ECO:0000269|Ref.17}.
FT   NP_BIND     140    143       NAD. {ECO:0000255|HAMAP-Rule:MF_03160,
FT                                ECO:0000269|PubMed:22076378,
FT                                ECO:0000269|PubMed:22767592,
FT                                ECO:0000269|Ref.17}.
FT   NP_BIND     249    251       NAD. {ECO:0000255|HAMAP-Rule:MF_03160,
FT                                ECO:0000269|PubMed:22076378,
FT                                ECO:0000269|PubMed:22767592,
FT                                ECO:0000269|Ref.17}.
FT   NP_BIND     275    277       NAD. {ECO:0000255|HAMAP-Rule:MF_03160,
FT                                ECO:0000269|PubMed:22076378,
FT                                ECO:0000269|PubMed:22767592,
FT                                ECO:0000269|Ref.17}.
FT   ACT_SITE    158    158       Proton acceptor. {ECO:0000255|HAMAP-
FT                                Rule:MF_03160,
FT                                ECO:0000269|PubMed:22076378}.
FT   METAL       166    166       Zinc. {ECO:0000255|HAMAP-Rule:MF_03160}.
FT   METAL       169    169       Zinc. {ECO:0000255|HAMAP-Rule:MF_03160}.
FT   METAL       207    207       Zinc. {ECO:0000255|HAMAP-Rule:MF_03160}.
FT   METAL       212    212       Zinc. {ECO:0000255|HAMAP-Rule:MF_03160}.
FT   BINDING     102    102       Substrate. {ECO:0000255|HAMAP-
FT                                Rule:MF_03160}.
FT   BINDING     105    105       Substrate. {ECO:0000255|HAMAP-
FT                                Rule:MF_03160}.
FT   BINDING     293    293       NAD; via amide nitrogen.
FT                                {ECO:0000255|HAMAP-Rule:MF_03160,
FT                                ECO:0000269|PubMed:22076378,
FT                                ECO:0000269|PubMed:22767592,
FT                                ECO:0000269|Ref.17}.
FT   VAR_SEQ       1    108       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042291.
FT   VAR_SEQ     189    206       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042292.
FT   VAR_SEQ     286    299       RFHFQGPCGTTLPE -> SHLISISSLIIIKN (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008730.
FT   VAR_SEQ     300    310       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_008731.
FT   VARIANT     285    285       F -> L (in dbSNP:rs9464003).
FT                                /FTId=VAR_029042.
FT   VARIANT     305    305       E -> G (in dbSNP:rs34162626).
FT                                /FTId=VAR_051980.
FT   MUTAGEN      69     69       T->A: Abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:23028781}.
FT   MUTAGEN     102    102       Y->F: Increases the KM for
FT                                desuccinylation.
FT                                {ECO:0000269|PubMed:22076378}.
FT   MUTAGEN     105    105       R->M: Increases the KM for
FT                                desuccinylation. Does not affect
FT                                deacetylase activity.
FT                                {ECO:0000269|PubMed:22076378,
FT                                ECO:0000269|PubMed:23028781}.
FT   MUTAGEN     158    158       H->A: Abolishes desuccinylation and
FT                                deglutarylation activity.
FT                                {ECO:0000269|PubMed:21908771,
FT                                ECO:0000269|PubMed:22076378,
FT                                ECO:0000269|PubMed:24703693}.
FT   CONFLICT     53     53       I -> M (in Ref. 2; BAG63757).
FT                                {ECO:0000305}.
FT   HELIX        40     49       {ECO:0000244|PDB:5BWL}.
FT   STRAND       51     57       {ECO:0000244|PDB:5BWL}.
FT   HELIX        59     63       {ECO:0000244|PDB:5BWL}.
FT   TURN         64     66       {ECO:0000244|PDB:5BWL}.
FT   STRAND       70     72       {ECO:0000244|PDB:3RIY}.
FT   HELIX        73     75       {ECO:0000244|PDB:3RIY}.
FT   HELIX        82     85       {ECO:0000244|PDB:5BWL}.
FT   HELIX        88     93       {ECO:0000244|PDB:5BWL}.
FT   HELIX        95    108       {ECO:0000244|PDB:5BWL}.
FT   HELIX       109    111       {ECO:0000244|PDB:5BWL}.
FT   HELIX       116    129       {ECO:0000244|PDB:5BWL}.
FT   TURN        130    132       {ECO:0000244|PDB:5BWL}.
FT   STRAND      134    139       {ECO:0000244|PDB:5BWL}.
FT   HELIX       145    148       {ECO:0000244|PDB:5BWL}.
FT   STRAND      153    156       {ECO:0000244|PDB:5BWL}.
FT   STRAND      159    166       {ECO:0000244|PDB:5BWL}.
FT   TURN        167    169       {ECO:0000244|PDB:5BWL}.
FT   STRAND      172    174       {ECO:0000244|PDB:5BWL}.
FT   STRAND      178    181       {ECO:0000244|PDB:5BWL}.
FT   HELIX       182    184       {ECO:0000244|PDB:5BWL}.
FT   STRAND      190    193       {ECO:0000244|PDB:4HDA}.
FT   HELIX       201    203       {ECO:0000244|PDB:5BWL}.
FT   TURN        210    212       {ECO:0000244|PDB:5BWL}.
FT   STRAND      215    220       {ECO:0000244|PDB:5BWL}.
FT   HELIX       229    241       {ECO:0000244|PDB:5BWL}.
FT   STRAND      243    250       {ECO:0000244|PDB:5BWL}.
FT   STRAND      252    254       {ECO:0000244|PDB:5BWL}.
FT   HELIX       257    259       {ECO:0000244|PDB:5BWL}.
FT   HELIX       261    266       {ECO:0000244|PDB:5BWL}.
FT   STRAND      271    277       {ECO:0000244|PDB:5BWL}.
FT   STRAND      284    291       {ECO:0000244|PDB:5BWL}.
FT   HELIX       293    300       {ECO:0000244|PDB:5BWL}.
SQ   SEQUENCE   310 AA;  33881 MW;  022DA32CDB43AC3A CRC64;
     MRPLQIVPSR LISQLYCGLK PPASTRNQIC LKMARPSSSM ADFRKFFAKA KHIVIISGAG
     VSAESGVPTF RGAGGYWRKW QAQDLATPLA FAHNPSRVWE FYHYRREVMG SKEPNAGHRA
     IAECETRLGK QGRRVVVITQ NIDELHRKAG TKNLLEIHGS LFKTRCTSCG VVAENYKSPI
     CPALSGKGAP EPGTQDASIP VEKLPRCEEA GCGGLLRPHV VWFGENLDPA ILEEVDRELA
     HCDLCLVVGT SSVVYPAAMF APQVAARGVP VAEFNTETTP ATNRFRFHFQ GPCGTTLPEA
     LACHENETVS
//
